These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1668553)

  • 1. In vitro immunomodulation and in vivo immunotherapy of retrovirus-induced immunosuppression.
    Good RA; Haraguchi S; Lorenz E; Day NK
    Int J Immunopharmacol; 1991; 13 Suppl 1():1-7. PubMed ID: 1668553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive actions of retroviruses.
    Good RA; Ogasawara M; Liu WT; Lorenz E; Day NK
    Lymphology; 1990 Jun; 23(2):56-9. PubMed ID: 2170777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections.
    Haraguchi S; Good RA; Cianciolo GJ; Engelman RW; Day NK
    J Leukoc Biol; 1997 Jun; 61(6):654-66. PubMed ID: 9201256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immunologic aspects of FeLV-induced immunosuppression.
    Ogilvie GK; Tompkins MB; Tompkins WA
    Vet Microbiol; 1988 Jul; 17(3):287-96. PubMed ID: 2847393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation by peptide analogs of retroviral envelope protein.
    Mehrotra S; Mishra KP; Yadav VS; Bhattacharya M; Pandey D; Haq W; Singh VK
    Peptides; 2003 Jul; 24(7):979-85. PubMed ID: 14499276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells.
    Littwitz-Salomon E; Dittmer U; Sutter K
    Retrovirology; 2016 Nov; 13(1):77. PubMed ID: 27821119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrovirus-mediated immunosuppression. II. FeLV-UV alters in vitro murine T lymphocyte behavior by reversibly impairing lymphokine secretion.
    Orosz CG; Zinn NE; Olsen RG; Mathes LE
    J Immunol; 1985 Jul; 135(1):583-90. PubMed ID: 2987350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of retrovirus suppression of human T cell proliferation in vitro.
    Copelan EA; Rinehart JJ; Lewis M; Mathes L; Olsen R; Sagone A
    J Immunol; 1983 Oct; 131(4):2017-20. PubMed ID: 6311904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference of retroviral envelope with vaccine-induced CD8
    Bongard N; Lapuente D; Windmann S; Dittmer U; Tenbusch M; Bayer W
    Retrovirology; 2017 Apr; 14(1):28. PubMed ID: 28449719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunodeficiency in latent feline leukemia virus infections.
    Lafrado LJ; Dezzutti CS; Lewis MG; Olsen RG
    Vet Immunol Immunopathol; 1989 May; 21(1):39-46. PubMed ID: 2549692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression.
    Dittmer U; Race B; Peterson KE; Stromnes IM; Messer RJ; Hasenkrug KJ
    J Virol; 2002 Jan; 76(1):450-4. PubMed ID: 11739713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity in receptor usage by T-cell-tropic feline leukemia viruses: implications for the in vivo tropism of immunodeficiency-inducing variants.
    Lauring AS; Anderson MM; Overbaugh J
    J Virol; 2001 Oct; 75(19):8888-98. PubMed ID: 11533152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyclonal activation of B-lymphocytes and induction of autoimmunity in retrovirus infected NMRI mice.
    Faxvaag A; Moen T; Dalen AB
    Scand J Immunol; 1993 Nov; 38(5):459-62. PubMed ID: 8235449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins.
    Cianciolo GJ; Copeland TD; Oroszlan S; Snyderman R
    Science; 1985 Oct; 230(4724):453-5. PubMed ID: 2996136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose of Retroviral Infection Determines Induction of Antiviral NK Cell Responses.
    Littwitz-Salomon E; Schimmer S; Dittmer U
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28904191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation of the Putative Immunosuppressive Domain of the Retroviral Envelope Glycoprotein Compromises Infectivity.
    Eksmond U; Jenkins B; Merkenschlager J; Mothes W; Stoye JP; Kassiotis G
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28814524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.
    Teigler JE; Zelinskyy G; Eller MA; Bolton DL; Marovich M; Gordon AD; Alrubayyi A; Alter G; Robb ML; Martin JN; Deeks SG; Michael NL; Dittmer U; Streeck H
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28904197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host genetic factors that control immune responses to retrovirus infections.
    Miyazawa M; Tsuji-Kawahara S; Kanari Y
    Vaccine; 2008 Jun; 26(24):2981-96. PubMed ID: 18255203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines.
    Orosz CG; Zinn NE; Olsen RG; Mathes LE
    J Immunol; 1985 May; 134(5):3396-403. PubMed ID: 2984289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Workshop summary on the immunotherapy of retrovirus infections. Armed Forces Retrovirus Research Group.
    Mil Med; 1990 Jun; 155(6):281-3. PubMed ID: 2172869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.